|
[1] 中华医学会肝病学分会、传染病与寄生虫病学分会.丙型肝炎防治指南[J].中华肝脏病杂志, 2004, 12 (4) :194-198.
|
|
[2]Strader DB, Wright T, Thomas DL, et al.American association forthe study of liver diseases[J].Hepatology, 2001, 34 (4) :A2-A5.
|
|
[3]Schinazi RF, Sommadossi JP, Thomas HC.Epidemiology, natural his-tory∥Therapies for viral hepatitis[C].RF:international medicalpress, 1998.
|
|
[4]Firpi RJ, Clark V, Soldevila-Pico C, et al.The natural history ofhepatitis C cirrhosis after liver transplantation[J].Liver Transpl, 2009, 15 (9) :1063-1071.
|
|
[5]Dieterich DT, Rizzetto M, Manns MP.Management of chronic hep-atitis C patients who have relapsed or not responded to pegylated in-terferon alfa plus ribavirin[J].J Viral Hepat, 2009, 16 (12) :833-843.
|
|
[6]Orlent H, Vrolijk JM, Veldt BJ, et al.Hepatitis C 2002 guide-lines:summary and annotations[J].Scand J Gastroenterol Suppl, 2003, (239) :105-110.
|
|
[7]Fried MW, Shiffman ML, Reddy KR, et al.Peginterferon alfa-2aplus ribavirin for chronic hepatitis C virus infection[J].N Engl JMed, 2002, 347 (13) :975-982.
|
|
[8]Manns MP, Mchutchison JG, Gordon SC, et al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirinfor initial treatment of chronic hepatitis C:a randomised trial[J].Lancet, 2001, 358 (9286) :958-965.
|
|
[9]Zeuzem S, Pawlotsky JM, Lukasiewicz E, et al.International, multi-center, randomized, controlled study comparing dynamically individual-ized versus standard treatment in patients with chronic hepatitis C[J].J Hepatol, 2005, 43 (2) :250-257.
|